NEULANDLAB2024-04-012024-06-30 NEULANDLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2024-06-30 NEULANDLAB2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524558 NEULANDLAB NOTLISTED Neuland Laboratories Limited Equity 2024-04-01 2025-03-31 2024-08-01 2024-07-17 INR Lakhs First quarter 12:25:00 15:00:00 2024-08-01 2024-08-01 Not applicable Single segment Manufacturing of Active Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Consolidated 4396017000.00 48070000.00 4444087000.00 1549513000.00 0.00 219317000.00 731379000.00 26705000.00 162799000.00 662210000.00 3351923000.00 1092164000.00 206256000.00 1298420000.00 305804000.00 13889000.00 319693000.00 0.00 978727000.00 0.00 0.00 0.00 0.00 978727000.00 -76000.00 978651000.00 0.00 0.00 0.00 0.00 129005000.00 10 76.28 76.28 0.00 0.00 76.28 76.28 1. The financial results for the quarter ended June 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 01, 2024. 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA (b) Neuland Laboratories KK., Japan. 4. The operations of the Company and its subsidiaries are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . 5. During the current quarter, the Company has transferred a part of its investment property situated at Nanakramguda, Hyderabad, Telangana, leading to profit of Rs. 2,062.56 lakhs which being exceptional in nature has been disclosed as a separate line Item. 6. Subsequent event disclosure: In light of the proposed amendment in Section 112, read in conjunction with Section 48 of the Income Tax Act 1961 with regards to reduction in tax rate along with removal of indexation benefit on long term capital gain, the Company is assessing its impact on the deferred tax asset created on indexation benefit on investment property. This being a non adjusting event, the impact of the same will be recorded in the books upon enactment of the Finance Act, 2024. 7. The EPS for quarters has not been annualised. 8. The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and year to date figures upto the third quarter ended December 31, 2023. Manufacturing expenses 361544000.00 Other expenses 300666000.00 Equity instruments through other comprehensive income 136000.00 136000.00 0.00 212000.00